Post-Market Clinical Follow-up Study of the Rechargeable Axonics SNM System Model 5101 (R20) for the Indication of Overactive Bladder (OAB)
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years or older
• Primary indication of OAB (urinary urgency incontinence (UUI) / urinary frequency (UF) who are not candidates for, or who have failed conservative treatment
• Willing and capable to provide written consent and agrees to comply with specified evaluations at clinical centers for all follow-up assessments
Locations
United States
Illinois
University of Chicago
RECRUITING
Chicago
Other Locations
United Kingdom
Bradford Royal Infirmary
RECRUITING
Bradford
University College London Hospital
RECRUITING
London
Pinderfields Hospital
RECRUITING
Wakefield
Contact Information
Primary
Anna Selverian
anna.selverian@bsci.com
714-262-1787
Backup
Erum Shaikh
Erum.Shaikh@bsci.com
657-626-4310
Time Frame
Start Date: 2025-09-18
Estimated Completion Date: 2031-10
Participants
Target number of participants: 55
Treatments
Other: Overactive Bladder
Participants with the Axonics SNM System Model 5101 and followed up regarding their overactive bladder symptoms.
Related Therapeutic Areas
Sponsors
Leads: Axonics, Inc.